Clinical Success of the Iovance TIL Technology Platform in Solid Tumors

Time: 10:30 am
day: Day Two


• Highlight advantages of polyclonal TIL MOA for solid tumors
• Review positive clinical data for TIL in metastatic melanoma and other solid tumor types
• Explore next-generation approaches: combinations and genetically modified TIL